Key Takeaways:

• Oriflame to sell manufacturing operations in India to a subsidiary of Akums Drugs and Pharmaceuticals Limited.
• Oriflame has operated in India for over 30 years, and it remains strategically important. 
• Akums Drugs and Pharmaceuticals Limited, one of India’s leading CDMOs, expands into color cosmetics with the deal.

Oriflame continues to optimize its global operations and sourcing footprint.

WHO: Oriflame is a global beauty and well-being company founded in Sweden in 1967. Operating in over 60 markets, the company offers a wide portfolio of innovative, high-quality, and sustainable beauty and well-being products.  Built on a social selling model, Oriflame supports a global community of approximately 3 million Beauty Entrepreneurs and members, empowering people to build businesses, develop skills, and express individuality through beauty. 

Akums Drugs and Pharmaceuticals Limited is one of India’s leading contract development and manufacturing organizations (CDMOs), delivering high-quality pharmaceutical, nutraceutical, and cosmetic products.

WHY: For Akums, the deal is part of a push beyond pharmaceuticals into the fast-growing color cosmetics category. The transaction forms part of Oriflame’s ongoing efforts to optimize its global operations and sourcing footprint while maintaining strong product quality, operational resilience, and service levels.

IN THEIR OWN WORDS: Anna Malmhake, CEO and President of Oriflame, said: “India is an important market for Oriflame and we remain fully committed to our long-term growth ambitions in the country. Through this strategic partnership with Akums, we are securing access to high-quality manufacturing...